Abstract
Infections with the fungus Talaromyces (formerly Penicillium) marneffei are rare in patients who do not have AIDS. We report disseminated T. marneffei infection in 4 hematology patients without AIDS who received targeted therapy with monoclonal antibodies against CD20 or kinase inhibitors during the past 2 years. Clinicians should be aware of this emerging complication, especially in patients from disease-endemic regions.
Keywords:
CD20; Talaromyces (Penicillium) marneffei; fungi; kinase inhibitors; monoclonal antibodies; obinutuzumab; rituximab; ruxolitinib; sorafenib.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antifungal Agents / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Immunocompromised Host*
-
Male
-
Middle Aged
-
Mycoses / drug therapy
-
Mycoses / immunology
-
Mycoses / microbiology*
-
Nitriles
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Pyrimidines
-
Rituximab / therapeutic use
-
Talaromyces*
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Antineoplastic Agents
-
Nitriles
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
Rituximab
-
ruxolitinib